The role of imaging and molecular imaging in the early detection of metabolic and cardiovascular dysfunctions

International Journal of Obesity

Volumn 34, Issue , 2010, Pages S67-S81

  Montet Abou, K ^a   Viallon, M ^a   Hyacinthe, J N ^a   Delattre, B ^a   Vallee, J P ^a   Didier, D ^a   Croisille, P ^b   Montet, X ^a,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LOUIS PRADEL HOSPITAL   (France)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cardiovascular diseases; Heart; Inflammation; Molecular imaging; Mri

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CELL VIABILITY; CONTRAST ENHANCEMENT; EARLY DIAGNOSIS; HEART MUSCLE CELL; HEART VENTRICLE FUNCTION; HUMAN; LIPID STORAGE; MEDIASTINUM; METABOLIC DISORDER; MOLECULAR IMAGING; MYOCARDIAL HIBERNATION; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC SYNDROME X; OBESITY;

EID: 78650090650     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.242     Document Type: Article

References (114)

1. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305–313.
2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–79.
3. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006; 144: 517–524.
4. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962; 1: 39–44.
5. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997; 336: 1350–1355.
6. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2: 271–278.
7. Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: A cardiovascular magnetic resonance study. Heart 2004; 90: 760–764.
8. Syed MA, Paterson DI, Ingkanisorn WP, Rhoads KL, Hill J, Cannon III RO, Reproducibility and inter-observervariability of dobutamine stress CMR in patients with severe coronary disease: Implications for clinical research. J Cardiovasc Magn Reson 2005; 7: 763–768.
9. Botnar RM, Nagel E. Structural and functional imaging by MRI. Basic Res Cardiol 2008; 103: 152–160.
10. Finn JP, Nael K, Deshpande V, Ratib O, Laub G. Cardiac MR imaging: State of the technology. Radiology 2006; 241: 338–354.
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.
12. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007; 34: 255–262.
13. Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete’s heart. A meta-analysis of cardiac structure and function. Circulation 2000; 101: 336–344.
14. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004; 25: 1940–1965.
15. Dulce MC, Mostbeck GH, Friese KK, Caputo GR, Higgins CB. Quantification of the left ventricular volumes and function with cine MR imaging: Comparison of geometric models with threedimensional data. Radiology 1993; 188: 371–376.
16. Spottiswoode BS, Zhong X, Hess AT, Kramer CM, Meintjes EM, Mayosi BM, Tracking myocardial motion from cine DENSE images using spatiotemporal phase unwrapping and temporal fitting. IEEE Trans Med Imaging 2007; 26: 15–30.
17. Wen H, Marsolo KA, Bennett EE, Kutten KS, Lewis RP, Lipps DB, Adaptive postprocessing techniques for myocardial tissue tracking with displacement-encoded MR imaging. Radiology 2008; 246: 229–240.
18. Hyacinthe JN, Ivancevic MK, Daire JL, Vallee JP. Feasibility of complementary spatial modulation of magnetization tagging in the rat heart after manganese injection. NMR Biomed 2008; 21: 15–21.
19. Mewton N, Croisille P, Revel D, Weber O, Higgins CB, Saeed M. Left ventricular postmyocardial infarction remodeling studied by combining MR-tagging with delayed MR contrast enhancement. Invest Radiol 2008; 43: 219–228.
20. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984; 153: 189–194.
21. Kellman P, Hernando D, Shah S, Zuehlsdorff S, Jerecic R, Mancini C, Multiecho dixon fat and water separation method for detecting fibrofatty infiltration in the myocardium. Magn Reson Med 2009; 61: 215–221.
22. Reeder SB, Robson PM, Yu H, Shimakawa A, Hines CD, McKenzie CA, Quantification of hepatic steatosis with MRI: The effects of accurate fat spectral modeling. J Magn Reson Imaging 2009; 29: 1332–1339.
23. Ma J. Dixon techniques for water and fat imaging. J Magn Reson Imaging 2008; 28: 543–558.
24. Lee WJ, Fattal G. Mediastinal lipomatosis in simple obesity. Chest 1976; 70: 308–309.
25. Lamb HJ, van der Meer RW, de Roos A, Bax JJ. Cardiovascular molecular MR imaging. Eur J Nucl Med Mol Imaging 2007; 34 (1): S99–S104.
26. Ingwall JS. How high does intracellular sodium rise during acute myocardial ischaemia? A view from NMR spectroscopy. Cardiovasc Res 1995; 29: 279.
27. Ouwerkerk R, Weiss RG, Bottomley PA. Measuring human cardiac tissue sodium concentrations using surface coils, adiabatic excitation, and twisted projection imaging with minimal T2 losses. J Magn Reson Imaging 2005; 21: 546–555.
28. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D’Ambrosia G, Arbique D, Vongpatanasin W, Myocardial triglycerides and systolic function in humans: In vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003; 49: 417–423.
29. van der Meer RW, Doornbos J, Kozerke S, Schar M, Bax JJ, Hammer S, Metabolic imaging of myocardial triglyceride content: Reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007; 245: 251–257.
30. Smith HL, Willius F. Adiposity of the heart: A clinical and pathologic study of one hundred and thirty-six obese patients. Arch int med 1933; 52: 911–931.
31. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784–1789.
32. Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 2005; 48: 1229–1237.
33. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008; 52: 1006–1012.
34. Lamb HJ, Smit JW, van der Meer RW, Hammer S, Doornbos J, de Roos A, Metabolic MRI of myocardial and hepatic triglyceride content in response to nutritional interventions. Curr Opin Clin Nutr Metab Care 2008; 11: 573–579.
35. Luss H, Schafers M, Neumann J, Hammel D, Vahlhaus C, Baba HA, Biochemical mechanisms of hibernation and stunning in the human heart. Cardiovasc Res 2002; 56: 411–421.
36. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999; 79: 609–634.
37. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146–1149.
38. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56: 978–985.
39. Narula J, Dawson MS, Singh BK, Amanullah A, Acio ER, Chaudhry FA, Noninvasive characterization of stunned, hibernating, remodeled and nonviable myocardium in ischemic cardiomyopathy. J Am Coll Cardiol 2000; 36: 1913–1919.
40. Gowda RM, Khan IA, Vasavada BC, Sacchi TJ. Reversible myocardial dysfunction: Basics and evaluation. Int J Cardiol 2004; 97: 349–353.
41. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989; 117: 211–221.
42. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002; 39: 1151–1158.
43. Judd RM, Kim RJ. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2002; 106: E6; author reply e6.
44. Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2001; 104: 2838–2842.
45. Marcu CB, Beek AM, van Rossum AC. Clinical applications of cardiovascular magnetic resonance imaging. CMAJ 2006; 175: 911–917.
46. Vogel-Claussen J, Rochitte CE, Wu KC, Kamel IR, Foo TK, Lima JA, Delayed enhancement MR imaging: Utility in myocardial assessment. Radiographics 2006; 26: 795–810.
47. Atkinson DJ, Burstein D, Edelman RR. First-pass cardiac perfusion: Evaluation with ultrafast MR imaging. Radiology 1990; 174: 757–762.
48. Ding S, Wolff SD, Epstein FH. Improved coverage in dynamic contrast-enhanced cardiac MRI using interleaved gradient-echo EPI. Magn Reson Med 1998; 39: 514–519.
49. Lubbers DD, Janssen CH, Kuijpers D, van Dijkman PR, Overbosch J, Willems TP, The additional value of first pass myocardial perfusion imaging during peak dose of dobutamine stress cardiac MRI for the detection of myocardial ischemia. Int J Cardiovasc Imaging 2008; 24: 69–76.
50. Schreiber WG, Schmitt M, Kalden P, Mohrs OK, Kreitner KF, Thelen M. Dynamic contrast-enhanced myocardial perfusion imaging using saturation-prepared TrueFISP. J Magn Reson Imaging 2002; 16: 641–652.
51. Vitanis V, Manka R, Boesiger P, Kozerke S. Accelerated cardiac perfusion imaging using k-t SENSE with SENSE training. Magn Reson Med 2009; 62: 955–965.
52. Cochet AA, Lorgis L, Lalande A, Zeller M, Beer JC, Walker PM, Major prognostic impact of persistent microvascular obstruction as assessed by contrast-enhanced cardiac magnetic resonance in reperfused acute myocardial infarction. Eur Radiol 2009; 19: 2117–2126.
53. Hombach V, Grebe O, Merkle N, Waldenmaier S, Hoher M, Kochs M, Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005; 26: 549–557.
54. Baer FM, Voth E, Schneider CA, Theissen P, Schicha H, Sechtem U. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995; 91: 1006–1015.
55. Cury RC, Cattani CA, Gabure LA, Racy DJ, de Gois JM, Siebert U, Diagnostic performance of stress perfusion and delayedenhancement MR imaging in patients with coronary artery disease. Radiology 2006; 240: 39–45.
56. Klem I, Heitner JF, Shah DJ, Sketch MH, Behar V, Weinsaft J, Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 2006; 47: 1630–1638.
57. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2009; 10: 220–230.
58. Hirata Y, Soeki T, Akaike M, Sakai Y, Igarashi T, Sata M. Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters. Biomed Pharmacother 2009; 63: 781–786.
59. Black MJ, D’Amore A, Auden A, Stamp L, Osicka T, Panagiotopoulos S, Chronic type 1 diabetes in spontaneously hypertensive rats leads to exacerbated cardiac fibrosis. Cardiovasc Pathol 2009 (in press).
60. Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: The effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol 2009; 105: 399–407.
61. Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, Influence of myocardial fibrosis on left ventricular diastolic function: Noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging 2009; 2: 437–443.
62. Alfakih K, Sparrow P, Plein S, Sivananthan MU, Walters K, Ridgway JP, Delayed enhancement imaging: Standardised segmental assessment of myocardial viability in patients with ST-elevation myocardial infarction. Eur J Radiol 2008; 66: 42–47.
63. Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26: 1081–1086.
64. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, Myocardial T1 mapping: Application to patients with acute and chronic myocardial infarction. Magn Reson Med 2007; 58: 34–40.
65. Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G, Sivananthan MU. Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study. Am J Roentgenol 2006; 187: W630–W635.
66. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1–100 MHz: Dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 1984; 11: 425–448.
67. Lauterbur P, Dias M, Rudin A. Augmentation of tissue water proton spin-lattice relaxation rates in vivo by addition of paramagnetic ions. Academic Press: New York, 1978.
68. Mendonca-Dias MH, Gaggelli E, Lauterbur PC. Paramagnetic contrast agents in nuclear magnetic resonance medical imaging. Semin Nucl Med 1983; 13: 364–376.
69. Hunter DR, Haworth RA, Berkoff HA. Cellular manganese uptake by the isolated perfused rat heart: A probe for the sarcolemma calcium channel. J Mol Cell Cardiol 1981; 13: 823–832.
70. Ochi R. The slow inward current and the action of manganese ions in guinea-pig’s myocardium. Pflugers Arch 1970; 316: 81–94.
71. Skjold A, Vangberg TR, Kristoffersen A, Haraldseth O, Jynge P, Larsson HB. Relaxation enhancing properties of MnDPDP in human myocardium. J Magn Reson Imaging 2004; 20: 948–952.
72. Haworth RA, Goknur AB, Berkoff HA. Measurement of Ca channel activity of isolated adult rat heart cells using 54Mn. Arch Biochem Biophys 1989; 268: 594–604.
73. Hu TC, Pautler RG, MacGowan GA, Koretsky AP. Manganeseenhanced MRI of mouse heart during changes in inotropy. Magn Reson Med 2001; 46: 884–890.
74. Vander Elst L, Colet JM, Muller RN. Spectroscopic and metabolic effects of MnCl2 and MnDPDP on the isolated and perfused rat heart. Invest Radiol 1997; 32: 581–588.
75. Wendland MF. Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to imaging of the heart. NMR Biomed 2004; 17: 581–594.
76. Flacke S, Allen JS, Chia JM, Wible JH, Periasamy MP, Adams MD, Characterization of viable and nonviable myocardium at MR imaging: Comparison of gadolinium-based extracellular and blood pool contrast materials versus manganese-based contrast materials in a rat myocardial infarction model. Radiology 2003; 226: 731–738.
77. Storey P, Danias PG, Post M, Li W, Seoane PR, Harnish PP, Preliminary evaluation of EVP 1001-1: A new cardiac-specific magnetic resonance contrast agent with kinetics suitable for steady-state imaging of the ischemic heart. Invest Radiol 2003; 38: 642–652.
78. Krombach GA, Saeed M, Higgins CB, Novikov V, Wendland MF. Contrast-enhanced MR delineation of stunned myocardium with administration of MnCl(2) in rats. Radiology 2004; 230: 183–190.
79. Grangier C, Tourniaire J, Mentha G, Schiau R, Howarth N, Chachuat A, Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 1994; 18: 888–896.
80. Montet X, Lazeyras F, Howarth N, Mentha G, Rubbia-Brandt L, Becker CD, Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom Imaging 2004; 29: 60–70.
81. Montet-Abou K, Montet X, Weissleder R, Josephson L. Transfection agent induced nanoparticle cell loading. Mol Imaging 2005; 4: 165–171.
82. Montet-Abou K, Montet X, Weissleder R, Josephson L. Cell internalization of magnetic nanoparticles using transfection agents. Mol Imaging 2007; 6: 1–9.
83. Kanno S, Wu YJ, Lee PC, Dodd SJ, Williams M, Griffith BP, Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 2001; 104: 934–938.
84. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: Emerging applications. J Am Coll Cardiol 2006; 47: 1328–1338.
85. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453–2458.
86. Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: Postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol 2002; 37: 405–411.
87. Trivedi RA, JM UK-I, Graves MJ, Cross JJ, Horsley J, Goddard MJ, In vivo detection of macrophages in human carotid atheroma: Temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004; 35: 1631–1635.
88. Montet-Abou K, Daire JL, Hyacinthe JN, Jorge-Costa M, Grosdemange K, Mach F, In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J 2009; 31: 1410–1420.
89. Spuentrup E, Ruhl KM, Botnar RM, Wiethoff AJ, Buhl A, Jacques V, Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation 2009; 119: 1768–1775.
90. Wang X, Jin PP, Zhou T, Zhao YP, Ding QL, Wang DB, MR molecular imaging of thrombus: Development and application of a Gd-based novel contrast agent targeting to P-selectin. Clin Appl Thromb Hemost 2009; 16: 177–183.
91. Ye F, Wu X, Jeong EK, Jia Z, Yang T, Parker D, A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem 2008; 19: 2300–2303.
92. Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, Agonist-antagonist dilemma in molecular imaging: Evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug Chem 2008; 19: 192–200.
93. Kung HF, Kung MP, Wey SP, Lin KJ, Yen TC. Clinical acceptance of a molecular imaging agent: A long march with [99mTc]TRODAT. Nucl Med Biol 2007; 34: 787–789.
94. Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009; 390: 624–629.
95. Funovics M, Montet X, Reynolds F, Weissleder R, Josephson L. Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia 2005; 7: 904–911.
96. Wyss C, Schaefer SC, Juillerat-Jeanneret L, Lagopoulos L, Lehr HA, Becker CD, Molecular imaging by micro-CT: Specific E-selectin imaging. Eur Radiol 2009; 19: 2487–2494.
97. Borden MA, Zhang H, Gillies RJ, Dayton PA, Ferrara KW. A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials 2008; 29: 597–606.
98. Klibanov AL, Rychak JJ, Yang WC, Alikhani S, Li B, Acton S, Targeted ultrasound contrast agent for molecular imaging of inflammation in high-shear flow. Contrast Media Mol Imaging 2006; 1: 259–266.
99. Lange N, Becker CD, Montet X. Molecular imaging in a (pre-) clinical context. Acta Gastroenterol Belg 2008; 71: 308–317.
100. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18: 321–325.
101. Bogdanov Jr A, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol Imaging 2002; 1: 16–23.
102. Perez JM, Josephson L, O’Loughlin T, Hogemann D, Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 2002; 20: 816–820.
103. Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo JL, Aikawa E, Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008; 117: 1153–1160.
104. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007; 49: 1993–2000.
105. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998; 4: 623–626.
106. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003; 108: 2270–2274.
107. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001; 19: 1141–1147.
108. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001; 104: 1280–1285.
109. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 2006; 49: 6087–6093.
110. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006; 8: 214–222.
111. Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ, Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology 2006; 241: 469–476.
112. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006; 114: 1504–1511.
113. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med 2005; 54: 718–724.
114. Sosnovik DE, Nahrendorf M, Panizzi P, Matsui T, Aikawa E, Dai G, Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging 2009; 2: 468–475.